Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan

9 November 2000

journal article
Published by Springer Nature in Cell Death & Differentiation

Vol. 7 (11) , 1127-1136
https://doi.org/10.1038/sj.cdd.4400746

Abstract

Cell death and differentiation is a monthly research journal focused on the exciting field of programmed cell death and apoptosis. It provides a single accessible source of information for both scientists and clinicians, keeping them up-to-date with advances in the field. It encompasses programmed cell death, cell death induced by toxic agents, differentiation and the interrelation of these with cell proliferation.

Keywords

This publication has 40 references indexed in Scilit:

Safety and antitumor activity of recombinant soluble Apo2 ligand
Journal of Clinical Investigation, 1999
The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain
Immunity, 1997
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Nature Genetics, 1997
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Science, 1997
The tumor strikes back: New data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology
Cell Death & Differentiation, 1997
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Journal of Biological Chemistry, 1996
Identification and characterization of a new member of the TNF family that induces apoptosis
Immunity, 1995
Clinical Implications of the p53 Tumor-Suppressor Gene
New England Journal of Medicine, 1993
Identification of human cancers deficient in antigen processing.
The Journal of Experimental Medicine, 1993
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma
European Journal Of Cancer, 1992